{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:16Z","timestamp":1793316556656,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R44AG059511"],"award-info":[{"award-number":["1R44AG059511"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and strongly correlates with the growing incidence of obesity and type II diabetes. We have developed a human-on-a-chip model composed of human hepatocytes and adipose tissue chambers capable of modeling the metabolic factors that contribute to liver disease development and progression, and evaluation of the therapeutic metformin. This model uses a serum-free, recirculating medium tailored to represent different human metabolic conditions over a 14-day period. The system validated the indirect influence of adipocyte physiology on hepatocytes that modeled important aspects of NAFLD progression, including insulin resistant biomarkers, differential adipokine signaling in different media and increased TNF-\u03b1-induced steatosis observed only in the two-tissue model. This model provides a simple but unique platform to evaluate aspects of an individual factor\u2019s contribution to NAFLD development and mechanisms as well as evaluate preclinical drug efficacy and reassess human dosing regimens.<\/jats:p>","DOI":"10.1038\/s41598-021-92264-2","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:05:05Z","timestamp":1624442705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation"],"prefix":"10.1038","volume":"11","author":[{"given":"Victoria L.","family":"Slaughter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Rumsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Boone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duaa","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimhan Narasimhan","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Shuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"92264_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2017","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"92264_CR2","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail, B. J. et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 23, 8263\u20138276. https:\/\/doi.org\/10.3748\/wjg.v23.i47.8263 (2017).","journal-title":"World J. Gastroenterol."},{"key":"92264_CR3","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","volume":"43","author":"GC Farrell","year":"2006","unstructured":"Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43, S99\u2013S112. https:\/\/doi.org\/10.1002\/hep.20973 (2006).","journal-title":"Hepatology"},{"key":"92264_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin, M. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am. J. Gastroenterol. 113, 1649\u20131659. https:\/\/doi.org\/10.1038\/s41395-018-0088-6 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"92264_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1111\/ajt.14017","volume":"16","author":"SA Fayek","year":"2016","unstructured":"Fayek, S. A., Quintini, C., Chavin, K. D. & Marsh, C. L. The current state of liver transplantation in the United States. Am. J. Transplant. 16, 3093\u20133104. https:\/\/doi.org\/10.1111\/ajt.14017 (2016).","journal-title":"Am. J. Transplant."},{"key":"92264_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","volume":"256","author":"VG Agopian","year":"2012","unstructured":"Agopian, V. G. et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann. Surg. 256, 624\u2013633. https:\/\/doi.org\/10.1097\/SLA.0b013e31826b4b7e (2012).","journal-title":"Ann. Surg."},{"key":"92264_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD) 67, 328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367 (2018).","journal-title":"Hepatology (Baltimore, MD)"},{"key":"92264_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12944-018-0762-0","volume":"17","author":"X Zhu","year":"2018","unstructured":"Zhu, X. et al. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. Lipids Health Dis. 17, 114\u2013114. https:\/\/doi.org\/10.1186\/s12944-018-0762-0 (2018).","journal-title":"Lipids Health Dis."},{"key":"92264_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08923970903252220","volume":"32","author":"D-S Kim","year":"2010","unstructured":"Kim, D.-S. et al. Metformin regulates palmitate-induced apoptosis and ER stress response in HepG2 liver cells. Immunopharmacol. Immunotoxicol. 32, 251\u2013257. https:\/\/doi.org\/10.3109\/08923970903252220 (2010).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"92264_CR10","doi-asserted-by":"publisher","first-page":"108802","DOI":"10.18632\/oncotarget.22163","volume":"8","author":"M-J Lin","year":"2017","unstructured":"Lin, M.-J. et al. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK\/LXR\u03b1 signaling pathway. Oncotarget 8, 108802\u2013108809. https:\/\/doi.org\/10.18632\/oncotarget.22163 (2017).","journal-title":"Oncotarget"},{"key":"92264_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/dom.13592","volume":"21","author":"CJ Green","year":"2019","unstructured":"Green, C. J., Marjot, T., Tomlinson, J. W. & Hodson, L. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?. Diabetes Obes. Metab. 21, 749\u2013760. https:\/\/doi.org\/10.1111\/dom.13592 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"92264_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/diseases6040093","volume":"6","author":"R Cholankeril","year":"2018","unstructured":"Cholankeril, R. et al. Anti-diabetic medications for the pharmacologic management of NAFLD. Diseases 6, 93. https:\/\/doi.org\/10.3390\/diseases6040093 (2018).","journal-title":"Diseases"},{"key":"92264_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab. Clin. Exp. 65, 1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012 (2016).","journal-title":"Metab. Clin. Exp."},{"key":"92264_CR14","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","volume":"24","author":"Y-L Fang","year":"2018","unstructured":"Fang, Y.-L., Chen, H., Wang, C.-L. & Liang, L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d. World J. Gastroenterol. 24, 2974\u20132983. https:\/\/doi.org\/10.3748\/wjg.v24.i27.2974 (2018).","journal-title":"World J. Gastroenterol."},{"key":"92264_CR15","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.21655","volume":"45","author":"K Yamaguchi","year":"2007","unstructured":"Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (Baltimore, MD) 45, 1366\u20131374. https:\/\/doi.org\/10.1002\/hep.21655 (2007).","journal-title":"Hepatology (Baltimore, MD)"},{"key":"92264_CR16","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (Baltimore, MD) 52, 1836\u20131846. https:\/\/doi.org\/10.1002\/hep.24001 (2010).","journal-title":"Hepatology (Baltimore, MD)"},{"key":"92264_CR17","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/jn\/135.11.2499","volume":"135","author":"WG Bergen","year":"2005","unstructured":"Bergen, W. G. & Mersmann, H. J. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J. Nutr. 135, 2499\u20132502. https:\/\/doi.org\/10.1093\/jn\/135.11.2499 (2005).","journal-title":"J. Nutr."},{"key":"92264_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","volume":"65","author":"GT Brown","year":"2016","unstructured":"Brown, G. T. & Kleiner, D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65, 1080\u20131086 (2016).","journal-title":"Metabolism"},{"key":"92264_CR19","doi-asserted-by":"publisher","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","volume":"294","author":"D Greco","year":"2008","unstructured":"Greco, D. et al. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1281-1287. https:\/\/doi.org\/10.1152\/ajpgi.00074.2008 (2008).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"92264_CR20","doi-asserted-by":"publisher","first-page":"e90954","DOI":"10.1172\/jci.insight.90954","volume":"1","author":"RE Feaver","year":"2016","unstructured":"Feaver, R. E. et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight 1, e90954 (2016).","journal-title":"JCI Insight"},{"key":"92264_CR21","doi-asserted-by":"publisher","first-page":"14297","DOI":"10.1038\/s41598-018-32722-6","volume":"8","author":"M Kozyra","year":"2018","unstructured":"Kozyra, M. et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci. Rep. 8, 14297. https:\/\/doi.org\/10.1038\/s41598-018-32722-6 (2018).","journal-title":"Sci. Rep."},{"key":"92264_CR22","doi-asserted-by":"publisher","first-page":"dmm033530","DOI":"10.1242\/dmm.033530","volume":"11","author":"M Parafati","year":"2018","unstructured":"Parafati, M., Kirby, R. J., Khorasanizadeh, S., Rastinejad, F. & Malany, S. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. Dis. Model. Mech. 11, dmm033530. https:\/\/doi.org\/10.1242\/dmm.033530 (2018).","journal-title":"Dis. Model. Mech."},{"key":"92264_CR23","doi-asserted-by":"publisher","first-page":"e0159729","DOI":"10.1371\/journal.pone.0159729","volume":"11","author":"M Gori","year":"2016","unstructured":"Gori, M. et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS ONE 11, e0159729\u2013e0159729. https:\/\/doi.org\/10.1371\/journal.pone.0159729 (2016).","journal-title":"PLoS ONE"},{"key":"92264_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3748\/wjg.v23.i2.204","volume":"23","author":"T Kostrzewski","year":"2017","unstructured":"Kostrzewski, T. et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J. Gastroenterol. 23, 204\u2013215. https:\/\/doi.org\/10.3748\/wjg.v23.i2.204 (2017).","journal-title":"World J. Gastroenterol."},{"key":"92264_CR25","doi-asserted-by":"publisher","first-page":"20030","DOI":"10.1038\/srep20030","volume":"6","author":"C Oleaga","year":"2016","unstructured":"Oleaga, C. et al. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci. Rep. 6, 20030 (2016).","journal-title":"Sci. Rep."},{"key":"92264_CR26","doi-asserted-by":"publisher","first-page":"33069","DOI":"10.1002\/btpr.3069","volume":"37","author":"C Oleaga","year":"2021","unstructured":"Oleaga, C. et al. A functional long-term serum-free human hepatic in vitro system for drug evaluation. Biotechnol. Prog. 37, 33069. https:\/\/doi.org\/10.1002\/btpr.3069 (2021).","journal-title":"Biotechnol. Prog."},{"key":"92264_CR27","doi-asserted-by":"publisher","first-page":"1805792","DOI":"10.1002\/adfm.201805792","volume":"29","author":"C Oleaga","year":"2019","unstructured":"Oleaga, C. et al. Long-term electrical and mechanical function monitoring of a human-on-a-chip system. Adv. Funct. Mater. 29, 1805792. https:\/\/doi.org\/10.1002\/adfm.201805792 (2019).","journal-title":"Adv. Funct. Mater."},{"key":"92264_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biomaterials.2018.07.062","volume":"182","author":"C Oleaga","year":"2018","unstructured":"Oleaga, C. et al. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. Biomaterials 182, 176\u2013190. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.07.062 (2018).","journal-title":"Biomaterials"},{"key":"92264_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.stemcr.2014.01.002","volume":"2","author":"WK Ong","year":"2014","unstructured":"Ong, W. K. et al. Identification of specific cell-surface markers of adipose-derived stem cells from subcutaneous and visceral fat depots. Stem Cell Rep. 2, 171\u2013179. https:\/\/doi.org\/10.1016\/j.stemcr.2014.01.002 (2014).","journal-title":"Stem Cell Rep."},{"key":"92264_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5115\/acb.2015.48.2.85","volume":"48","author":"A-A Ghoniem","year":"2015","unstructured":"Ghoniem, A.-A., A\u00e7il, Y., Wiltfang, J. & Gierloff, M. Improved adipogenic in vitro differentiation: comparison of different adipogenic cell culture media on human fat and bone stroma cells for fat tissue engineering. Anat. Cell Biol. 48, 85\u201394. https:\/\/doi.org\/10.5115\/acb.2015.48.2.85 (2015).","journal-title":"Anat. Cell Biol."},{"key":"92264_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2217\/17460875.3.5.545","volume":"3","author":"BK Surmi","year":"2008","unstructured":"Surmi, B. K. & Hasty, A. H. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol. 3, 545\u2013556. https:\/\/doi.org\/10.2217\/17460875.3.5.545 (2008).","journal-title":"Future Lipidol."},{"key":"92264_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.febslet.2007.11.051","volume":"582","author":"WP Cawthorn","year":"2008","unstructured":"Cawthorn, W. P. & Sethi, J. K. TNF-\u03b1 and adipocyte biology. FEBS Lett. 582, 117\u2013131. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.051 (2008).","journal-title":"FEBS Lett."},{"key":"92264_CR33","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/dmd.115.065979","volume":"43","author":"SJ Woolsey","year":"2015","unstructured":"Woolsey, S. J., Mansell, S. E., Kim, R. B., Tirona, R. G. & Beaton, M. D. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug. Metab. Dispos. 43, 1484\u20131490. https:\/\/doi.org\/10.1124\/dmd.115.065979 (2015).","journal-title":"Drug. Metab. Dispos."},{"key":"92264_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","volume":"12","author":"SA Polyzos","year":"2010","unstructured":"Polyzos, S. A., Kountouras, J., Zavos, C. & Tsiaousi, E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes. Metab. 12, 365\u2013383. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01176.x (2010).","journal-title":"Diabetes Obes. Metab."},{"key":"92264_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/716404","volume":"2012","author":"A Mazza","year":"2012","unstructured":"Mazza, A. et al. The role of metformin in the management of NAFLD. Exp. Diabetes Res. 2012, 716404. https:\/\/doi.org\/10.1155\/2012\/716404 (2012).","journal-title":"Exp. Diabetes Res."},{"key":"92264_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1177\/1933719113488441","volume":"20","author":"R Erices","year":"2013","unstructured":"Erices, R. et al. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod. Sci. 20, 1433\u20131446. https:\/\/doi.org\/10.1177\/1933719113488441 (2013).","journal-title":"Reprod. Sci."},{"key":"92264_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000381643","volume":"24","author":"M Kinaan","year":"2015","unstructured":"Kinaan, M., Ding, H. & Triggle, C. R. Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium. Med. Princ. Pract. 24, 401\u2013415. https:\/\/doi.org\/10.1159\/000381643 (2015).","journal-title":"Med. Princ. Pract."},{"key":"92264_CR38","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI19246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796\u20131808. https:\/\/doi.org\/10.1172\/JCI19246 (2003).","journal-title":"J. Clin. Invest."},{"key":"92264_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.immuni.2014.05.010","volume":"41","author":"JC McNelis","year":"2014","unstructured":"McNelis, J. C. & Olefsky, J. M. Macrophages, immunity, and metabolic disease. Immunity 41, 36\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2014.05.010 (2014).","journal-title":"Immunity"},{"key":"92264_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.2627","volume":"18","author":"O Osborn","year":"2012","unstructured":"Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363\u2013374. https:\/\/doi.org\/10.1038\/nm.2627 (2012).","journal-title":"Nat. Med."},{"key":"92264_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","volume":"49","author":"E Cobbina","year":"2017","unstructured":"Cobbina, E. & Akhlaghi, F. Non-alcoholic fatty liver disease (NAFLD)\u2014pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab. Rev. 49, 197\u2013211. https:\/\/doi.org\/10.1080\/03602532.2017.1293683 (2017).","journal-title":"Drug Metab. Rev."},{"key":"92264_CR42","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00204-016-1689-8","volume":"90","author":"H Rashidi","year":"2016","unstructured":"Rashidi, H., Alhaque, S., Szkolnicka, D., Flint, O. & Hay, D. C. Fluid shear stress modulation of hepatocyte-like cell function. Arch. Toxicol. 90, 1757\u20131761 (2016).","journal-title":"Arch. Toxicol."},{"key":"92264_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","volume":"66","author":"J Poisson","year":"2017","unstructured":"Poisson, J. et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J. Hepatol. 66, 212\u2013227 (2017).","journal-title":"J. Hepatol."},{"key":"92264_CR44","doi-asserted-by":"publisher","first-page":"E859","DOI":"10.1152\/ajpendo.00165.2014","volume":"307","author":"GM Kowalski","year":"2014","unstructured":"Kowalski, G. M. & Bruce, C. R. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am. J. Physiol. Endocrinol. Metab. 307, E859-871. https:\/\/doi.org\/10.1152\/ajpendo.00165.2014 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"92264_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3803\/EnM.2013.28.1.41","volume":"28","author":"YY Seo","year":"2013","unstructured":"Seo, Y. Y. et al. Tumor necrosis factor-alpha as a predictor for the development of nonalcoholic fatty liver disease: a 4-year follow-up study. Endocrinol. Metab. (Seoul) 28, 41\u201345. https:\/\/doi.org\/10.3803\/EnM.2013.28.1.41 (2013).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"92264_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676. https:\/\/doi.org\/10.1038\/nmeth.2019 (2012).","journal-title":"Nat. Methods"},{"key":"92264_CR47","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1093\/bioinformatics\/btw413","volume":"32","author":"D Legland","year":"2016","unstructured":"Legland, D., Arganda-Carreras, I. & Andrey, P. MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ. Bioinformatics 32, 3532\u20133534. https:\/\/doi.org\/10.1093\/bioinformatics\/btw413 (2016).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92264-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:12:29Z","timestamp":1670062349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92264-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92264"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92264-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm that competing financial interests exist but there has been no financial support for this research that could have influenced its outcome. J.J.H. has ownership interest and is Chief Scientist and member of the Board of Directors in a company that may benefit financially as a result of the outcomes of the research or work reported in this publication. No other authors have a competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13159"}}